From simply delicious water to healthy water. HOME SITE MAP Japanese
Nihon Trim Co.,Ltd. People,Life,Water Company Guide Research and Development Investor Relations
Return to Research and Development
HOME >> Research and Development >> PLoS ONE Abstract of paper published in September, 2017
Related Infomation
Abstracts of Scientific Papers
(September 2017)
(February 2017)
Renal Replacement Therapy
(March 2016)
Environmental Control
In Biology
(July 2014)
Medical Gas Research
(December 2013)
Hemodial International
(November 2013)
(July 2012)
(June 2012)
Trends in Food Science and Technology
(November 2011)
BMC Proceedings
(November 2011)
BMC Proceedings
(November 2011)
and Biochemistry
(July 2011)
Nephrology Dialysis Transplantation
(December 2010)
(November 2010)
and Biochemistry
(October 2010)
Nephrology Dialysis Transplantation
(April 2010)
Nephrology Dialysis Transplantation
(February 2010)
Free Radical Research
(January 2010)
Nephron Clinical Practice
(April 2009)
(June 2008)
Biological & Pharmaceutical Bulletin
(January 2008)
Hemodialysis International
(June 2007)
Kidney International
(July 2006)
(January 2005)
Kidney International
Vol.64 (July 2003)
(June 2003)
(May 1997)
List of Papers and Conference Presentations on Electrolyzed Reduced Water
What is electrolyzed reduced water?
Environmental Control In Biology (2014) Abstract of paper published in July 2014
Effects of Deoxidized Nutrient Solution on Growth of Komatsuna (Brassica rapa var. perviridis) Plants

Background and aim:It is supposed that enhanced oxidative stress and inflammation are involved with the poor clinical outcomes in patients on chronic dialysis treatment. Recent studies have shown that molecular hydrogen (H2) is biologically active as an anti-inflammatory agent. Thus, we developed a novel hemodialysis (E-HD) system which delivers H2 (30 to 80 ppb)-enriched dialysis solution, to conduct a prospective observational study (UMIN000004857) in order to compare the long-term outcomes between E-HD and conventional-HD (C-HD) in Japan. The present interim analysis aimed to look at potential clinical effects of E-HD during the first 12 months observation.

Subjects and method:262 patients (140, E-HD; 122, C-HD) were subjected for analysis for comprehensive clinical profiles. They were all participating in the above mentioned study, and they had been under the respective HD treatment for 12 consecutive months without hospitalization. Collected data, such as, physical and laboratory examinations, medications, and self-assessment questionnaires on subjective symptoms (i.e., fatigue and pruritus) were compared between the two groups.

Results:In a 12-month period, no clinical relevant differences were found in dialysis-related parameters between the two groups. However, there were differences in the defined daily dose of anti-hypertensive agents, and subjective symptoms, such as severe fatigue, and pruritus, which were all less in the E-HD group. Multivariate analysis revealed E-HD was an independent significant factor for the reduced use of anti-hypertensive agents as well as the absence of severe fatigue and pruritus at 12 months after adjusting for confounding factors.

ConclusionThe data indicates E-HD could have substantial clinical benefits beyond conventional HD therapy, and support the rationale to conduct clinical trials of H2 application to HD treatment.

Page Top
Nihon Trim Co.,Ltd.
Headquarters: 22nd Floor, Herbis Ent Office Tower, 2-2-22 Umeda, kita-ku, Osaka, 530-0001
Tel: +81-6-6456-4600
Personal Information Protection Policy
Copyright 2006 Nihon Trim Co.,Ltd. All rights reserved. Unauthorized reproduction of illustrations, photographs,or trademarks on this Web site is prohibited.